An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder

Psychopharmacology Bulletin

Volumn 32, Issue 1, 1996, Pages 175-180

  Phillips, Katharine A ^a,b  

^a BUTLER HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

augmentation; body dysmorphic disorder; buspirone; serotonin reuptake inhibitors; somatoform disorders

Indexed keywords

BUSPIRONE; CLOMIPRAMINE; FLUOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; BODY IMAGE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DELUSION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERANCE; FATIGUE; FEMALE; HUMAN; MALE; NAUSEA; OBSESSION; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME;

ADULT; BUSPIRONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PROGNOSIS; SEROTONIN UPTAKE INHIBITORS;

EID: 0029935901     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: The Association, 1994.
2. Brawman-Mintzer, O; Lydiard, RB; Phillips, KA; Morton, A; Czepowicz, V; Emmanuel, N; Villareal, G; Johnson, M; and Ballenger, JC. Body dysmorphic disorder in patients with anxiety disorders and major depression: A comorbidity study. Am. J. Psychiatry 152:1665-1667, 1995.
3. Eisen, JL; Phillips, KA; Beer, D; Rasmussen, SA; and Goodman, WK. Assessment of insight in obsessions and delusions. 1993 New Research Program and Abstracts. San Francisco, CA: American Psychiatric Association, 1993. p. 149.
4. Eisen, JL; Rasmussen, SA; Phillips, KA; Lydiard, RB; and Pigott, TA. Does degree of insight in OCD predict improvement? 1995 New Research Program and Abstracts. Miami, FL: American Psychiatric Association, 1995. p. 154.
5. Goodman, WK; McDougle, CJ; Barr, LC; Aronson, SC; and Price, LH. Biological approaches to treatment-resistant obsessive compulsive disorder. J. Clin. Psychiatry 54(S):16-26, 1993.
6. Grady, TA; Pigott, TA; L'Heureux, F; Hill, JL; Bernstein, SE; and Murphy, DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am. J. Psychiatry 150:819-821, 1993.
7. Grady, TA; Pigott, TA; L'Heureux, F; and Murphy, DL. Seizure associated with fluoxetine and adjuvant buspirone therapy (letter). J. Clin. Psychopharmacol. 12:70-71, 1992.
8. Hollander, E; Cohen, LJ; and Simeon, D. Body dysmorphic disorder. Psychiatr. Ann. 23:359-364, 1993.
9. Hollander, E; Liebowitz, MR; Winchel, R; Klumker, A; and Klein, DF. Treatment of body-dysmorphic disorder with serotonin reuptake blockers. Am. J. Psychiatry 146:768-770, 1989.
10. Hollander, E, and Phillips, KA. Body image and experience disorders: Body dysmorphic and depersonalization disorders. In: Hollander, E, ed. Obsessive Compulsive-Related Disorders. Washington, DC: American Psychiatric Press, 1993. pp. 17-48.
11. Hudson, JI, and Pope, HG Jr. Affective spectrum disorder: Does antidepressant response identify a family of disorders with a common pathophysiology? Am. J. Psychiatry 147:553-564, 1990.
12. Jacobsen, FM. Possible augmentation of antidepressant response by buspirone. J. Clin. Psychiatry 52:217-220, 1991.
13. Jenike, MA, and Baer, L. An open trial of buspirone in obsessive-compulsive disorder. Am. J. Psychiatry 145:1285-1286, 1988.
14. Jenike, MA; Baer, L; and Buttolph, L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J. Clin. Psychiatry 52:13-16, 1991.
15. Joffe, RT, and Schuller, DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J. Clin. Psychiatry 54:269-271, 1993.
16. Markovitz, PJ; Stagno, SJ; and Calabrese, JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am. J. Psychiatry 147:798-800, 1990.
17. McDougle, CJ; Goodman, WK; Leckman, JF; Holzer, JC; Barr, LC; McCance-Katz, E; Heninger, GR; and Price, LH. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry 150:647-649, 1993.
18. McDougle, CJ; Goodman, WK; Price, LH; Delgado, PL; Krystal, JH; Charney, DS; and Heninger, GR. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am. J. Psychiatry 147:652-654, 1990.
19. McElroy, SL; Phillips, KA; and Keck, PE Jr. Obsessive-compulsive spectrum disorders. J. Clin. Psychiatry 55(S):33-51, 1994.
20. National Institute of Mental Health. Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 1985.
21. Pato, MT; Pigott, TA; Hill, JL; Grover, GN; Bernstein, S; and Murphy, DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am. J. Psychiatry 148:127-129, 1991.
22. Phillips, KA; Atala, KD; and Pope, HG. Diagnostic instruments for body dysmorphic disorder. 1995 New Research Program and Abstracts. Miami, FL: American Psychiatric Association, 1995a. p. 157.
23. Phillips, KA; McElroy, SL; Hudson, JI; and Pope, HG Jr. Body dysmorphic disorder: An obsessive compulsive spectrum disorder, a form of affective spectrum disorder, or both? J. Clin. Psychiatry 56(S):41-51, 1995b.
24. Phillips, KA; McElroy, SL; Keck, PE Jr; Pope, HG Jr; and Hudson, JI. Body dysmorphic disorder. 30 cases of imagined ugliness. Am. J. Psychiatry 150:302-308, 1993.
25. Phillips, KA; McElroy, SL; Keck, PE Jr; Pope, HG Jr; and Hudson, JI. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol. Bull. 30:179-186, 1994.
26. Phillips, KA, and Nierenberg, AA. The assessment and treatment of refractory depression. J. Clin. Psychiatry 55(S):20-26, 1994.
27. Phillips, KA; Nierenberg, AA; Brendel, G; and Fava, M. Prevalence and clinical features of body dysmorphic disorder in atypical major depression. J. Nerv. Ment. Dis., in press 1996.
28. Pollock, BG. Recent developments in drug metabolism of relevance to psychiatrists. Harvard Rev. Psychiatry 2:204-213, 1994.
29. Sathananthan, GL; Sanghvi, I; Phillips, N; and Gershon, S. MJ 9022: Correlation between neuroleptic potential and stereo-typy. Curr. Ther. Res. 18:701-705, 1975.
30. Spitzer, RL; Williams, JBW; Gibbon, M; and First, MB. The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Arch. Gen. Psychiatry 49:624-629, 1992.
31. Sussman, N. The uses of buspirone in psychiatry. J. Clin. Psychiatry Monograph 12:3-19, 1994.